A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO7434656, AN ANTISENSE INHIBITOR OF COMPLEMENT FACTOR B, IN PATIENTS WITH PRIMARY IgA NEPHROPATHY AT HIGH RISK OF PROGRESSION
Internal Medicine
Nephrology
Kidney Disease
Adult Subjects
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.